Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

What this study is about

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).

Who can join (things the study team will check)

✅ You may be able to join if…

• Age 12-17
• Depression and/or anxiety as the primary concern, confirmed by the treating physician
• Intention to start a new SSRI
• English fluency

🚫 You may not be able to join if…

• Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
• History of non-response to 3 or more SSRI medications as confirmed by the treating physician
• Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
• History of liver or hematopoietic cell transplant
• History of CYP2B6, CYP2C19, or CYP2D6 testing

Where this trial is running

• University of Calgary, Calgary, Alberta, Canada

Who to contact

Madison Heintz, MSW · 587-223-3154 · gap@ucalgary.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06853587.